Plainsboro, N.J. (PRWEB) July 15, 2014
OncLive® is pleased to announce that Yale Cancer Center has joined its Strategic Alliance Partnership program.
Participating in the Strategic Alliance Partnership program will enable Yale Cancer Center to work with the OncLive team to raise awareness of its efforts to deliver patient-centered care, achieve breakthrough discoveries, and train future leaders in cancer science and medicine.
Yale Cancer Center has been a National Cancer Institute (NCI)-designated comprehensive cancer center for more than 40 years, and is one of only 41 such organizations in the country. Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven have 12 multidisciplinary cancer programs, a robust portfolio of advanced clinical trials, and offer patients and their families, expert and compassionate care. Treatment at Yale increasingly places an emphasis on targeted therapies incorporating a patient’s particular cancer subtype and genetic profile.
In addition to providing cutting-edge personalized, multidisciplinary cancer care, Yale Cancer Center clinicians and scientists make significant contributions in basic and translational research. Research at Yale includes programs in developmental therapeutics, cancer genetics and genomics, molecular virology, cancer immunology, signal transduction, cancer prevention and control, and radiobiology. Yale researchers are engaged in projects designed to encourage collaborative research, such as the Cancer Biology Institute.
Mike Hennessy, Jr., Vice President of Sales and Marketing and leader of the oncology division of Intellisphere, the publisher of OncLive, said, “Yale Cancer Center has long been a pioneer in cancer treatment and drug development. We look forward to partnering with such a renowned and prestigious institution that shares our mission of supporting oncologists, nurses, and other oncology professionals in their
Copyright©2014 Vocus, Inc.
All rights reserved